NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Collaboration supports multiple discovery efforts, including vaccines
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Bringing next-gen cannabinoid therapeutics to cancer patients
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Subscribe To Our Newsletter & Stay Updated
